NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: INNOVACAP · data 2026-10-31
Innova Captab Limited
In plain words
Price: 24.2% below its 52-week high of ₹1,353.5.
Delivery: 45.6% of traded shares were kept for delivery over the last 10 sessions, against 45.4% over the last 60.
Latest results: a net profit of ₹44 cr for the quarter ended Jun 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹1,749 cr |
| Net profit (last 12 months) | ₹156 cr |
| Sales growth, 3 years (yearly) | 20.1% |
| Profit growth, 3 years (yearly) | 28.2% |
At a glance
Promoters 50.9% (unchanged in a year), pledged 0.0%, institutions 20.0%.
P/E 37.5, dividend yield 0.2%. Price relative to earnings and book value (low is cheaper, not better).
ROE 14.0%, ROCE 12.9%, operating margin 12.2%: how much profit it earns on the money it uses.
Debt/equity 0.32, Profit growth 28.2% and sales growth 20.1% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Profit grew 28.2% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
INNOVACAP Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹470.85 crore.
Net profit was ₹44.13 crore.
Operating margin was 15.5%.
EPS was ₹7.71.
INNOVACAP के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹470.85 करोड़।
शुद्ध मुनाफ़ा: ₹44.13 करोड़।
ऑपरेटिंग मार्जिन: 15.5%।
EPS: ₹7.71।
INNOVACAPના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹470.85 કરોડ.
ચોખ્ખો નફો: ₹44.13 કરોડ.
ઓપરેટિંગ માર્જિન: 15.5%.
EPS: ₹7.71.
Written from the filed numbers. Not a recommendation.
Smart-money activity
17/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 7/30: Delivery 45.1% over the last 20 sessions vs 37.9% in the 40 before (1.19x); shares delivered per day 0.68x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 5/15: 2 schemes hold it, about ₹129 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 21 Aug 26Results Results board meeting -2.0% next session
- 11 Aug 26Results Q1 FY27 results: net profit ₹44.1 cr +4.8% next session
- 7 May 26Results Results board meeting +0.3% next session
- 30 Jan 26Dividend Dividend ₹2 (ex-date) +2.5% next session
- 23 Jan 26Results Results board meeting +7.1% next session
- 7 Nov 25Results Results board meeting -7.8% next session
- 7 Aug 25Results Results board meeting -1.1% next session
- 19 May 25Results Results board meeting -1.4% next session
- 5 Feb 25Results Q3 FY25 results: net profit ₹34.2 cr -5.7% next session
- 7 Nov 24Results Results board meeting +12.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹471 cr | ₹44 cr | — | 15.5% | 7.71 |
| Dec 2024 | ₹316 cr | ₹34 cr | — | 14.7% | 5.97 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 50.90% | 50.90% | 50.90% | 50.90% |
| Foreign institutions (FII) | 0.84% | 0.34% | 0.23% | 0.11% |
| Domestic institutions (DII) | 19.16% | 19.92% | 20.14% | 20.24% |
| Mutual funds | 8.66% | 9.18% | 10.50% | 10.58% |
| Retail investors | 5.35% | 5.15% | 4.92% | 5.01% |
| Number of shareholders | 36,551 | 35,881 | 36,965 | 38,691 |
Common questions
What was Innova Captab Limited's latest quarterly profit?
Innova Captab Limited reported a net profit of ₹44 cr for the quarter ended Jun 2026, on revenue of ₹471 cr.
How much do promoters hold in Innova Captab Limited?
Promoters held 50.90% of Innova Captab Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Innova Captab Limited debt-free?
Its latest reported debt-to-equity ratio is 0.32.
What is Innova Captab Limited's P/E ratio?
About 37.5, based on the last 12 months' earnings and a price of ₹1,025.3 (data 2026-10-31).
What is the 52-week high and low of Innova Captab Limited?
The 52-week high is ₹1,353.5 and the 52-week low is ₹622.
Mutual funds holding Innova Captab Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 2 schemes holding about ₹129 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 1.65% | ₹97 cr |
| SBI Balanced Hybrid Fund | SBI Mutual Fund | 1.63% | ₹32 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Innova Captab Limited | ₹1,025.3 | ₹5,900 cr | 37.5 | — | 14% | 12.9% | 0.32 | +25.7% |
| Supriya Lifescience Limited | ₹847.3 | ₹6,810 cr | 34.4 | — | 19.1% | 22.3% | 0 | +13.4% |
| Morepen Laboratories Limited | ₹113.35 | ₹6,230 cr | 32.9 | 4.5 | 7.9% | 6.2% | 0.17 | +132.3% |
| FDC Ltd. | ₹377 | ₹6,132 cr | 19.6 | 2.3 | 11.8% | 11.7% | 0.01 | -14.9% |
| Sun Pharma Advanced Research Co. Ltd. | ₹176.46 | ₹5,741 cr | 3.6 | — | 276.9% | 232.1% | 0.42 | +27.9% |
| Senores Pharmaceuticals Ltd. | ₹1,133.9 | ₹5,221 cr | 39.2 | 5.2 | 13.4% | 12.6% | 0.37 | +46.7% |
Compare INNOVACAP with SUPRIYA in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open INNOVACAP in NSE Scanner →